Sugi Predict

Sugi Predict / Compounds / SCHEMBL4928282

SCHEMBL4928282

SCHEMBL4928282

CC(C)(C)OC(=O)c1cccc(CN)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 3/20 0.69
▸ SLC7A5 Q01650 2/20 0.66
▸ HTR2C P28335 1/20 0.47
▸ CYP4F2 P78329 3/20 0.46
▸ CYP4A11 Q02928 3/20 0.46
▸ STAT3 P40763 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ ENPP2 Q13822 1/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ MRGPRX4 Q96LA9 1/20 0.41
▸ CFD P00746 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA3 P34903 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2316080 0.98 LOXL2 (0.67) LOXL2SLC7A5HTR2CCYP4F2CYP4A11
SCHEMBL27440895 0.88 LOXL2 (0.61) LOXL2SLC7A5HTR2CCYP4F2CYP4A11
SCHEMBL7504785 0.88 SLC7A5 (0.63) LOXL2SLC7A5CYP4F2CYP4A11STAT3
SCHEMBL12301533 0.87 SLC7A5 (0.65) LOXL2SLC7A5CYP4F2CYP4A11STAT3
SCHEMBL3499880 0.85 SLC7A5 (0.63) LOXL2SLC7A5CYP4F2CYP4A11STAT3
SCHEMBL7384982 0.85 SLC7A5 (0.63) LOXL2SLC7A5CYP4F2CYP4A11STAT3
SCHEMBL31688987 0.85 SLC7A5 (0.60) LOXL2SLC7A5CYP4F2CYP4A11STAT3
SCHEMBL27796426 0.84 LOXL2 (0.65) LOXL2SLC7A5HTR2CCYP4F2CYP4A11
SCHEMBL27355641 0.84 LOXL2 (0.56) LOXL2SLC7A5HTR2CCYP4F2CYP4A11
SCHEMBL1246082 0.84 SLC7A5 (0.62) LOXL2SLC7A5CYP4F2CYP4A11STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719602-A1 ANTI-HIV COMPOUNDS GILEAD SCIENCES, INC. (US) 2026-04-08 — — EP disclosed
US-20250084077-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS ASTEX THERAPEUTICS LIMITED (GB) 2025-03-13 — — US disclosed
US-20250051375-A1 ANTI-HIV COMPOUNDS GILEAD SCIENCES, INC. 2025-02-13 — — US disclosed
WO-2024249517-A1 ANTI-HIV COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-12-05 — — WO disclosed
US-12091409-B2 Ether linked triazoles as NRF2 activators ASTEX THERAPEUTICS LIMITED (GB) 2024-09-17 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-20220089590-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS ASTEX THERAPEUTICS LIMITED (GB) 2022-03-24 — — US disclosed
EP-3555082-B1 ETHER LINKED TRIAZOLES AS NRF2 REGULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2022-01-26 — — EP disclosed
US-11059816-B2 Ether linked triazoles as NRF2 activators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-07-13 — — US disclosed
US-6894057-B2 Oxo-azabicyclic compounds WARNER-LAMBERT COMPANY (US) 2005-05-17 — — US disclosed
EP-1492775-A2 OXO-AZABICYCLIC COMPOUNDS Warner-Lambert Company LLC (US) 2005-01-05 — — EP disclosed
US-6747147-B2 INHIBITORS OF TYPE-13 MATRIX METTALOPROTEASE. RHEUMATOID ARTHRITIS OR OSTEOARTHRITIS, AS WELL AS CERTAIN PROLIFERATIVE CONDITIONS SUCH AS CANCERS, PARTICULARLY HUMAN BREAST CANCER WARNER-LAMBERT COMPANY 2004-06-08 — — US disclosed
US-20030220355-A1 Oxo-azabicyclic compounds GAUDILLIERE BERNARD (FR) 2003-11-27 — — US disclosed
US-20030216402-A1 Oxo-azabicyclic compounds GAUDILLIERE BERNARD (FR) 2003-11-20 — — US disclosed
WO-2003076416-A1 OXO AZABICYCLIC COMPOUNDS WARNER-LAMBERT COMPANY LLC (US) 2003-09-18 — — WO disclosed
WO-2003076417-A2 OXO-AZABICYCLIC COMPOUNDS WARNER-LAMBERT COMPANY LLC (US) 2003-09-18 — — WO disclosed
EP-0400290-A1 5-Amino-4-hydroxyvalerianic acid derivatives useful as intermediates in the preparation of renin inhibitors CIBA-GEIGY AG (CH) 1990-12-05 — — EP disclosed
EP-0144290-A2 Substituted ethylenediamine derivatives CIBA-GEIGY AG (CH) 1985-06-12 — — EP disclosed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216402-A1 Oxo-azabicyclic compounds MMP13, CYP2A13, XDH LOXL2 431/4885SLC7A5 2175/4885HTR2C 2194/4885
US-11059816-B2 Ether linked triazoles as NRF2 activators NFE2L2, KEAP1, NQO1 LOXL2 2105/4885SLC7A5 3836/4885HTR2C 1821/4885
US-20220089590-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS NFE2L2, KEAP1, NQO1 LOXL2 2105/4885SLC7A5 3836/4885HTR2C 1821/4885
US-20030220355-A1 Oxo-azabicyclic compounds MMP13, CYP2A13, CA13 LOXL2 537/4885SLC7A5 2318/4885HTR2C 2259/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS LOXL2 3342/4885SLC7A5 1341/4885HTR2C 149/4885
US-20250084077-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS NFE2L2, KEAP1, NQO1 LOXL2 2105/4885SLC7A5 3836/4885HTR2C 1821/4885
US-20250051375-A1 ANTI-HIV COMPOUNDS CCR5, CD4, NFATC1 LOXL2 4369/4885SLC7A5 628/4885HTR2C 4642/4885
US-12091409-B2 Ether linked triazoles as NRF2 activators NFE2L2, KEAP1, NQO1 LOXL2 2105/4885SLC7A5 3836/4885HTR2C 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.